Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
651 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Exercise Training in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
Hammer S, Toussaint M, Vollsæter M, et al. · J Rehabil Med · 2022Meta-Analysis, Systematic Review
- Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis.
Crisafulli S, Sultana J, Fontana A, et al. · Orphanet J Rare Dis · 2020Meta-Analysis, Research Support, Non-U.S. Gov't
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Mendell JR, Muntoni F, McDonald CM, et al. · Nat Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Global prevalence of Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis.
Salari N, Fatahi B, Valipour E, et al. · J Orthop Surg Res · 2022Meta-Analysis, Systematic Review
- Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis.
Leone E, Pandyan A, Rogers A, et al. · J Neurol Neurosurg Psychiatry · 2024Meta-Analysis, Systematic Review
- Predictors of Loss of Ambulation in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis.
Landfeldt E, Alemán A, Abner S, et al. · J Neuromuscul Dis · 2024Systematic Review, Meta-Analysis
- Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta-analysis.
Weber FJ, Latshang TD, Blum MR, et al. · Muscle Nerve · 2022Meta-Analysis, Systematic Review
- Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis.
Broomfield J, Hill M, Guglieri M, et al. · Neurology · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. · Lancet Neurol · 2024Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Clemens PR, Perlman SJ, et al. · JAMA Neurol · 2022Multicenter Study, Randomized Controlled Trial
- Newborn screening of neuromuscular diseases.
Dangouloff T, Boemer F, Servais L · Neuromuscul Disord · 2021Systematic Review
- Family Involvement and at-Home Physical Therapy on Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Hernández-Sánchez A, Parra-Sánchez L, Montolio M, et al. · Pediatr Neurol · 2024Randomized Controlled Trial
- The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review.
Ryder S, Leadley RM, Armstrong N, et al. · Orphanet J Rare Dis · 2017Systematic Review
- Strength training and aerobic exercise training for muscle disease.
Voet NB, van der Kooi EL, van Engelen BG, et al. · Cochrane Database Syst Rev · 2019Meta-Analysis, Research Support, Non-U.S. Gov't
- Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Bushby K, McDermott MP, et al. · JAMA · 2022Comparative Study, Randomized Controlled Trial
- Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E, Brassington R, Kuntzer T, et al. · Cochrane Database Syst Rev · 2016Meta-Analysis, Research Support, Non-U.S. Gov't
- Population pharmacokinetic-pharmacodynamic analysis of givinostat.
Fiorentini F, Germani M, Del Bene F, et al. · Expert Opin Drug Metab Toxicol · 2023Clinical Trial, Phase II
- Histological effects of givinostat in boys with Duchenne muscular dystrophy.
Bettica P, Petrini S, D'Oria V, et al. · Neuromuscul Disord · 2016Clinical Trial, Phase II
- Eteplirsen for the treatment of Duchenne muscular dystrophy.
Mendell JR, Rodino-Klapac LR, Sahenk Z, et al. · Ann Neurol · 2013Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.
Dang UJ, Damsker JM, Guglieri M, et al. · Neurology · 2024Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR, Rao VK, Connolly AM, et al. · JAMA Neurol · 2020Clinical Trial, Phase II, Multicenter Study
- Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
McDonald CM, Marbán E, Hendrix S, et al. · Lancet · 2022Clinical Trial, Phase II, Multicenter Study
- Pharmacotherapy of Duchenne Muscular Dystrophy.
Hoffman EP · Handb Exp Pharmacol · 2020Clinical Trial
- Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial.
McDonald CM, Shieh PB, Abdel-Hamid HZ, et al. · J Neuromuscul Dis · 2021Clinical Trial, Phase III, Multicenter Study
- Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation.
Hind D, Parkin J, Whitworth V, et al. · Health Technol Assess · 2017Multicenter Study, Randomized Controlled Trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.